Yeast-Built Nanozyme Exoskeleton Eases Gut Inflammation and the Anxiety That Comes With It

One of the most quietly debilitating aspects of inflammatory bowel disease has never been fully explained by the inflammation itself. For a large share of patients living with Crohn’s disease and ulcerative colitis, the chronic gut disorder travels with an unwelcome companion: anxiety and depression that can persist even when intestinal symptoms are brought under control. The co-occurrence is not merely psychological weariness from living with a long-term illness. Growing evidence suggests that inflammatory signals, a disrupted gut barrier, and an unbalanced microbiome communicate along the gut-brain axis, feeding mood disturbances in ways that standard anti-inflammatory drugs and standard psychiatric medications each fail to resolve on their own. A new study published in Nature Communications now proposes an unusually inventive answer to this dual problem, one built from yeast cell walls, metal-oxide nanoparticles, and a chemical strategy borrowed from insects.

The research team, led by Fan Zhang, Lei Chen, Yong Liu, and Jian Xiao, with collaborators at Wenzhou Medical University, Oujiang Laboratory, and Nankai University, describes a family of materials they call nanozyme-exoskeletonized yeast-derived polysaccharides, abbreviated NZEP. The central idea is a fusion of two biologically familiar components. The first is a polysaccharide scaffold derived from yeast, which provides a large, biocompatible, and biodegradable structure that the digestive tract already knows how to tolerate. The second is a layer of nanozymes, artificial nanoparticles that mimic the catalytic activity of natural enzymes, grafted onto that scaffold in a dense external coating. The result is a microscopic composite that behaves like a single, robust particle with the surface chemistry of yeast and the catalytic power of an enzyme-mimicking nanomaterial.

What makes the construction method particularly striking is its natural model. Rather than relying on conventional polymer chemistry to lock the nanozymes onto the polysaccharide surface, the researchers drew inspiration from insect sclerotization, the process by which insects harden and stabilize their exoskeletons. In sclerotization, phenolic compounds, notably quinone derivatives generated from catechols such as dopamine-like molecules, undergo oxidative coupling and cross-linking reactions that convert a soft cuticle into a tough, chemically resistant armor. By adapting this chemistry, the team was able to coat yeast-derived polysaccharides with a stable, integrated layer of nanozymes, producing what they describe as a series of materials with varying degrees of exoskeletonization. The most heavily armored member of the series, designated NZEP-TA-Ce, emerged as the leading candidate, combining a tannic-acid-based phenolic framework with cerium-based catalytic nanoparticles.

The choice of cerium is central to the material’s therapeutic logic. Cerium oxide nanoparticles are among the most studied antioxidant nanozymes, capable of cycling between cerium(III) and cerium(IV) oxidation states in a way that lets them scavenge reactive oxygen species catalytically, repeatedly, and without being consumed. In the inflamed intestine, oxidative stress is a self-perpetuating driver of tissue damage: reactive oxygen species injure epithelial cells, recruit immune cells, and stimulate further inflammatory signaling, which in turn generates more reactive oxygen species. By embedding catalytic antioxidant activity directly into the particle shell, NZEP-TA-Ce is designed to interrupt this vicious cycle at the source, quenching the oxidative messengers that keep the inflammatory loop running.

The study’s mechanistic findings point to exactly that interruption. According to the authors, NZEP-TA-Ce inhibits inflammatory signaling mediated by two of the most important molecular pathways in intestinal inflammation: the mitogen-activated protein kinase cascade, or MAPK, and the NF-κB pathway. These pathways act as master switches in immune cells and epithelial cells, translating stress and inflammatory stimuli into the production of pro-inflammatory cytokines. When they are chronically activated, as they are in inflammatory bowel disease, the result is a sustained cycle of immune activation, tissue damage, and barrier breakdown. Suppressing both routes simultaneously, the researchers report, allows the material to disrupt the inflammatory feedback loop that sustains the disease, rather than merely damping individual symptoms downstream.

A second advantage of the yeast-derived scaffold lies in its behavior after oral administration, which is the route that matters most for a gut-directed therapy. In mouse models of inflammatory bowel disease, orally delivered NZEP-TA-Ce showed effective retention and accumulation in inflamed colonic regions rather than being washed through indiscriminately. This targeting behavior is thought to arise from interactions between the polysaccharide shell and components of the inflamed tissue environment, an effect long exploited by other yeast-derived microparticles that bind to inflamed intestinal surfaces. Once retained at the site of injury, the material reversed the imbalance of intestinal inflammation and promoted repair of the intestinal barrier, the single-cell-thick lining whose leakage is considered a key event linking gut inflammation to systemic immune activation and, by extension, to disturbances in mood-related brain signaling.

The third and perhaps most novel dimension of the study concerns the gut microbiota. NZEP-TA-Ce treatment reversed dysbiosis, the characteristic disruption in the composition of the intestinal microbial community that accompanies inflammatory bowel disease. The microbiome is not a passive bystander in either the gut disease or its psychiatric comorbidities. Microbial metabolites, including short-chain fatty acids and other small molecules produced by bacteria as they ferment dietary fiber, travel through the bloodstream and act on immune cells, the vagus nerve, and brain circuits involved in anxiety and depression. The researchers report that the treatment optimized the composition of these microbial metabolites, restoring a metabolic profile more consistent with a healthy gut community. In doing so, the therapy addressed the molecular messengers thought to carry inflammatory and mood-related signals between gut and brain.

The combined effect of these three actions, catalytic anti-inflammatory activity, barrier repair, and microbiota modulation, translated into behavioral improvement in the animal models. Mice receiving NZEP-TA-Ce showed alleviation of the anxiety-like and depressive symptoms associated with inflammatory bowel disease, in parallel with the improvement in their intestinal pathology. This is the aspect of the work most likely to capture attention beyond the gastroenterology community, because it demonstrates in a single orally delivered material a therapeutic strategy aimed simultaneously at a physical disease and its psychological comorbidities. Most existing approaches treat the two conditions in parallel with separate drugs, an approach that ignores the mechanistic overlap the gut-brain axis research of recent years has done so much to illuminate.

The study also emphasized safety, a nontrivial consideration for any nanomaterial intended for repeated oral use. Yeast-derived polysaccharides such as beta-glucans have a long history of safe dietary and pharmaceutical use, and the exoskeletonization strategy embeds the catalytic metal particles within a biocompatible matrix, potentially limiting their free interaction with host tissues. The work was supported by the National Natural Science Foundation of China, the National Science and Technology Major Project for Innovative Drug Research and Development, the Natural Science Foundation of Zhejiang Province, and municipal research programs in Wenzhou, and it was conducted with institutional support from Wenzhou Medical University and Oujiang Laboratory. The authors report no competing interests.

As with any mouse study, the distance to human medicine remains substantial. Human inflammatory bowel disease is more heterogeneous than the models used in the laboratory, and behavioral readouts in mice only approximate the clinical experience of anxiety and depression. Dosing, long-term biodistribution of the cerium nanozymes, and manufacturing consistency at scale will all require further work before clinical trials could be contemplated. Even so, the study stands out as a demonstration of a design philosophy likely to shape future research: rather than choosing between anti-inflammatory drugs, barrier protectants, and microbiome therapies, it combines all three functions in one bioinspired composite, using nature’s own engineering solutions, from insect armor to yeast architecture, as the blueprint. For the millions of patients whose bowel disease and mood disorder reinforce one another, that integrated vision of treatment is a direction worth watching closely.

Subject of Research: A nanozyme-exoskeletonized yeast polysaccharide therapy for inflammatory bowel disease with comorbid anxiety and depression

Article Title: Bioinspired nanozyme-exoskeletonized yeast-derived polysaccharides for treating comorbid anxiety and depression in inflammatory bowel disease

Article References: Bioinspired nanozyme-exoskeletonized yeast-derived polysaccharides for treating comorbid anxiety and depression in inflammatory bowel disease. (n.d.). https://doi.org/10.1038/s41467-026-78633-3

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78633-3

Keywords: nanozymes, yeast polysaccharides, inflammatory bowel disease, anxiety, depression, gut-brain axis, gut microbiota, intestinal barrier, NF-kB, MAPK, cerium oxide, biomaterials